Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy (usually cytarabine) often develops; therefore a new treatment modality is needed. Bcl-2 family proteins play an important role in balancing cell survival and apoptosis. The antiapoptotic Bcl-2 family proteins have been found to be dysregulated in AML. ABT-199, a BH3 mimetic, was developed to target antiapoptotic protein Bcl-2. Although ABT-199 has demonstrated promising results, resistance occurs. Previous studies in AML show that ABT-199 alone decreases the association of proapoptotic protein Bim with Bcl-2, but this is compensated by increased association of Bim with prosurvival protein Mcl-1, stabilizing Mcl-1, resulting in resistance to ABT-199. In this study, we investigated the antileukemic activity of the Mcl-1-selective inhibitor A-1210477 in combination with ABT-199 in AML cells. We found that A-1210477 synergistically induced apoptosis with ABT-199 in AML cell lines and primary patient samples. The synergistic induction of apoptosis was decreased upon Bak, Bax and Bim knockdown. While A-1210477 treatment alone also increased Mcl-1 protein levels, combination with ABT-199 reduced binding of Bim to Mcl-1. Our results demonstrate that sequestration of Bim by Mcl-1, a mechanism of ABT-199 resistance, can be abrogated by combined treatment with the Mcl-1 inhibitor A-1201477.

• Publication year

  2017

• Venue

  Signal Transduction and Targeted Therapy

• Publication date

  2017-04-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sigtrans.2017.12PMID 29263915PMCID 5661618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?

  2016cited by this paper
• Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

  2016cited by this paper
• Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

  2015cited by this paper
• Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage

  2015cited by this paper
• Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

  2015cited by this paper
• Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

  2015cited by this paper
• MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

  2015cited by this paper
• CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

  2014cited by this paper
• Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199

  2014cited by this paper
• Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

  2014cited by this paper
• BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

  2013cited by this paper
• Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

  2013cited by this paper
• Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition

  2013cited by this paper
• The vascular niche: home for normal and malignant hematopoietic stem cells

  2012cited by this paper
• Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells

  2012cited by this paper
• Targeting the B-cell lymphoma/leukemia 2 family in cancer.

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• γH2AX: a sensitive molecular marker of DNA damage and repair

  2010cited by this paper
• Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia

  2010cited by this paper
• Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

  2009cited by this paper
• RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

  2009cited by this paper
• An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation.

  2008cited by this paper
• The Bcl-2 apoptotic switch in cancer development and therapy

  2007cited by this paper
• Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

  2005cited by this paper
• DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells.

  2003cited by this paper
• Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.

  2003cited by this paper
• Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity.

  1999cited by this paper
• The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines.

  1997cited by this paper
• High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate

  1997cited by this paper
• Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.

  1996cited by this paper
• Cancer statistics

  1989cited by this paper

• Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.

  2026cites this paper
• Zinc(II)-berberine-based complexes targeting mitochondria exhibit enhanced antiproliferative activity as single drugs or in combination with ABT-199.

  2025cites this paper
• Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

  2025cites this paper
• Na+/H+ Exchanger 1 Inhibition Overcomes Venetoclax Resistance in Acute Myeloid Leukemia

  2025cites this paper
• Blocking β-adrenergic receptor signaling enhances the sensitivity of AML to MCL-1 inhibitor S63845.

  2025cites this paper
• Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment

  2024cites this paper
• Precision medicine in AML: overcoming resistance

  2024cites this paper
• Comprehensive review of Bcl‐2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules

  2024cites this paper
• Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights

  2024cites this paper
• Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.

  2024cites this paper
• The Effects of ABT-199 and Dihydroartemisinin Combination on Cell Growth and Apoptosis in Human U937 and KG-1 Cancer Cells

  2024cites this paper
• Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway

  2024cites this paper
• Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

  2024cites this paper
• MCL1 Inhibitor Augmented the Anti‐Glioma Efficacy of Paclitaxel Utilizing a Multifunctional Cascade Nanodrug System

  2024cites this paper
• Targeting Bcl-2 with Indole Scaffolds: Emerging Drug Design Strategies for Cancer Treatment.

  2024cites this paper
• KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

  2024cites this paper
• Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed.

  2024cites this paper
• AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells.

  2023cites this paper
• Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression

  2023cites this paper
• The Effects of Resveratrol, Gallic Acid, and Piperine on the Expression of miR-17, miR-92b, miR-181a, miR-222, BAX, BCL-2, MCL-1, WT1, c-Kit, and CEBPA in Human Acute Myeloid Leukemia Cells and Their Roles in Apoptosis

  2023cites this paper
• Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1/BCL-xL inhibitor are tolerated

  2023cites this paper
• Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice

  2023cites this paper
• Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy

  2023cites this paper
• Acquired Resistance to Venetoclax plus Azacitidine in Acute Myeloid Leukemia: in vitro Models and Mechanisms.

  2023cites this paper
• Combined Usage of Navitoclax and A-1210477 to Treat AcuteLymphoblastic Leukemia

  2023cites this paper
• Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199.

  2023cites this paper
• Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax

  2023cites this paper
• Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.

  2023cites this paper
• A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells

  2023cites this paper
• BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells.

  2022cites this paper
• Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression

  2022cites this paper
• Halogenated boroxine increases propensity to apoptosis in leukemia (UT‐7) but not non‐tumor cells in vitro

  2022cites this paper
• Sensitization effect of kaempferol from persimmon leaves on HepG2 hepatoma cells with ABT-199 resistance and its molecular mechanisms

  2022cites this paper
• Triple targeted therapy is a new perspective treatment strategy for patients with FLT3-mutated acute myeloid leukemia. the literature review and single-centre experience

  2022cites this paper
• Interaction between moxifloxacin and Mcl-1 and MITF proteins: the effect on growth inhibition and apoptosis in MDA-MB-231 human triple-negative breast cancer cells

  2022cites this paper
• Co-targeting of HDAC, PI3K, and Bcl-2 Results in Metabolic and Transcriptional Reprogramming and Decreased Mitochondrial Function in Acute Myeloid Leukemia.

  2022cites this paper
• c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia

  2022cites this paper
• Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma

  2022cites this paper
• Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.

  2022cites this paper
• Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway.

  2022cites this paper
• Cotargeting of Bcl-2 and Mcl-1 Shows Promising Antileukemic Activity against AML Cells Including those with Acquired Cytarabine Resistance.

  2021cites this paper
• Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?

  2021cites this paper
• Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

  2021cites this paper
• Mitochondrial metabolism as a target for acute myeloid leukemia treatment

  2021influential citation
• NOXA‐mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin‐treated human acute myeloid leukemia cells

  2021cites this paper
• Targeting Bcl-2 for cancer therapy.

  2021cites this paper
• Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.

  2021cites this paper
• Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.

  2021cites this paper
• Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation

  2021cites this paper
• Insights into the Role of Defective Apoptosis in Cancer Pathogenesis and Therapy

  2021cites this paper
• A review on myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.

  2021cites this paper
• Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism

  2021cites this paper
• Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia

  2021cites this paper
• The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

  2021cites this paper
• Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway

  2021cites this paper
• BH3-mimetics: recent developments in cancer therapy

  2021cites this paper
• LOR-253 Overcomes Resistance to ABT-199 by Targeting MTF1 in AML

  2021cites this paper
• Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

  2021influential citation
• Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

  2021cites this paper
• Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

  2021cites this paper
• Plenary Paper

  2021cites this paper
• The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study.

  2020cites this paper
• Targeting MCL-1 in hematologic malignancies: Rationale and progress.

  2020influential citation
• Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

  2020cites this paper
• 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models

  2020cites this paper
• Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

  2020cites this paper
• FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia

  2020cites this paper
• Apoptosis targeted therapies in acute myeloid leukemia: an update

  2020cites this paper
• Targeting DNA Repair Pathways in Hematological Malignancies

  2020cites this paper
• The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

  2020cites this paper
• Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

  2020cites this paper
• Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway

  2020cites this paper
• The changing molecular landscape of AML and its impact on treatment

  2020cites this paper
• GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells

  2020influential citation
• Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression

  2020cites this paper
• Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.

  2020cites this paper
• Multiple myeloma gammopathies BCL 2 blockade overcomes MCL 1 resistance in multiple myeloma

  2019cites this paper
• Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes

  2019cites this paper
• Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

  2019cites this paper
• Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

  2019cites this paper
• Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches

  2019cites this paper
• Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells

  2019cites this paper
• Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo

  2019cites this paper
• Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

  2019cites this paper
• A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

  2019cites this paper
• Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477

  2019cites this paper
• Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism

  2019influential citation
• Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL

  2019cites this paper
• Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia

  2019cites this paper
• Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways

  2019cites this paper
• Venetoclax for AML: changing the treatment paradigm.

  2019cites this paper
• A novel circular RNA (hsa_circ_0000370) increases cell viability and inhibits apoptosis of FLT3-ITD-positive acute myeloid leukemia cells by regulating miR-1299 and S100A7A.

  2019cites this paper
• The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome

  2019cites this paper
• CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

  2019cites this paper
• miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis

  2019cites this paper
• CMAR_A_180724 3197..3213

  2019cites this paper
• A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.

  2019cites this paper
• What are the most promising new agents in myelodysplastic syndromes?

  2019cites this paper
• MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells

  2019cites this paper
• Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

  2019cites this paper